Q-omics provides the consensus-scored CCDC110 profile across patient tissues and cancer cell-line models. CCDC110 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC110 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CCDC110 RNA expression shows 18,439 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where CCDC110 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC110 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC110 survival associations across molecular data types. CCDC110 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC110 RNA expression–survival associations across cancer types. High CCDC110 expression shows unfavorable associations in MESO, LIHC and BLCA, but favorable associations in KIRC, KIRP and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC110 RNA expression.
This table summarizes CCDC110 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC110. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC110 shows lower tumor expression in THCA, BLCA and STAD and higher tumor expression in KIRC, LIHC and LUAD. The THCA box plot shows higher CCDC110 RNA expression in normal versus tumor tissue (log2 FC = −2.100, t-test p < 0.001).
This table shows molecular features associated with CCDC110 in patient tissues and cancer cell lines. In patient samples, CCDC110 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC110 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
